High S100A9 level predicts poor survival, and the S100A9 inhibitor paquinimod is a candidate for treating idiopathic pulmonary fibrosis

MLA

Takeshi Masuda, et al. “High S100A9 Level Predicts Poor Survival, and the S100A9 Inhibitor Paquinimod Is a Candidate for Treating Idiopathic Pulmonary Fibrosis.” BMJ Open Respiratory Research, vol. 11, no. 1, June 2024. EBSCOhost, https://doi.org/10.1136/bmjresp-2023-001803.

APA

Takeshi Masuda, Hiroshi Iwamoto, Shintaro Miyamoto, Noboru Hattori, Taku Nakashima, Kazunori Fujitaka, Shinichiro Ohshimo, Shinichiro Miura, Masashi Namba, Kakuhiro Yamaguchi, Shinjiro Sakamoto, Yasushi Horimasu, & Hironobu Hamada. (2024). High S100A9 level predicts poor survival, and the S100A9 inhibitor paquinimod is a candidate for treating idiopathic pulmonary fibrosis. BMJ Open Respiratory Research, 11(1). https://doi.org/10.1136/bmjresp-2023-001803

Chicago

Takeshi Masuda, Hiroshi Iwamoto, Shintaro Miyamoto, Noboru Hattori, Taku Nakashima, Kazunori Fujitaka, Shinichiro Ohshimo, et al. 2024. “High S100A9 Level Predicts Poor Survival, and the S100A9 Inhibitor Paquinimod Is a Candidate for Treating Idiopathic Pulmonary Fibrosis.” BMJ Open Respiratory Research 11 (1). doi:10.1136/bmjresp-2023-001803.